N-乙基-3-氟苄胺 | 90389-85-8

• 物质功能分类: 有机原料 - 氨基化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-乙基-3-氟苄胺
• 中文别名: N-(3-氟苄基)-1-乙胺
• 英文名称: N-(3-fluorobenzyl)ethanamine
• 英文别名: N-Ethyl-3-fluorobenzylamine；N-[(3-fluorophenyl)methyl]ethanamine
• CAS: 90389-85-8
• 化学式: C₉H₁₂FN
• mdl: MFCD06655514
• 分子量: 153.199
• InChiKey: QAPAPLIQQTVEJZ-UHFFFAOYSA-N

物化性质

• 沸点：
  190.7±15.0 °C(Predicted)
• 密度：
  1.009±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2921499090
• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H315,H319

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N-Ethyl-3-fluorobenzylamine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: N-Ethyl-3-fluorobenzylamine
CAS number: 90389-85-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H12FN
Molecular weight: 153.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-乙基-3-氟苄胺 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 生成 6-(5-chloro-2-hydroxyphenyl)-2-(6-(ethyl(3-fluorobenzyl)amino)hexyl)pyridazin-3(2H)-one
  参考文献：
  名称：

  开发新型 2-氨基烷基-6-(2-羟基苯基)哒嗪-3(2H)-one 衍生物作为抗阿尔茨海默病的平衡多功能药物

  摘要：

  基于多靶点定向配体方法，通过两轮筛选，设计、合成了一系列2-氨基烷基-6-(2-羟基苯基)哒嗪-3( 2H )-one衍生物作为抗阿尔茨海默病的创新多功能药物. 体外生物学试验表明，大多数杂种具有很强的 AChE 抑制活性、优异的抗氧化活性和适度的 A β 1-42聚集抑制作用。综合考虑功效和平衡，12a被确定为具有显着抑制AChE的最佳多功能配体（Ee AChE，IC 50  = 0.20 μM；Hu AChE，IC 50 = 37.02 nM) 和抗 A β活性（ 自诱导 A β 1-42聚集的 IC 50 = 1.92 μM；A β 1-42原纤维分解的 IC 50  = 1.80 μM ；  Cu 2的 IC 50 = 2.18 μM + -诱导的 A β 1-42聚集；对于 Cu 2+ -诱导的 A β 1-42原纤维的解聚，IC 50  = 1.17 μM ；对于Hu AChE

  DOI：

  10.1016/j.ejmech.2021.114098
• 作为产物：
  描述：

  Ethyl-[1-(3-fluoro-phenyl)-meth-(E)-ylidene]-amine 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 反应 2.0h， 生成 N-乙基-3-氟苄胺
  参考文献：
  名称：

  Benzylamines: synthesis and evaluation of antimycobacterial properties

  摘要：

  The synthesis of benzylamines with various N-alkyl chains and substituents in the aromatic system as well as their evaluation on Mycobacterium tuberculosis H 37 Ra are described. The most active compounds in this test, N-methyl-3-chlorobenzylamine (19, MIC 10.2 micrograms/mL), N-methyl-3,5-dichlorobenzylamine (93, MIC 10.2 micrograms/mL), and N-butyl-3,5-difluorobenzylamine (103, MIC 6.4 micrograms/mL), also exhibited a marked inhibitory effect on Mycobacterium marinum and Mycobacterium lufu used for the determination of antileprotic properties. The combinations of 93 with aminosalicylic acid, streptomycin, or dapsone exert marked supra-additive effects on M. tuberculosis H 37 Ra.

  DOI：

  10.1021/jm00375a005

文献信息

• Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives
  申请人：Doyle Kevin James

  公开号：US20090318429A1

  公开（公告）日：2009-12-24

  The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-14 or encompassed by formulas I-XII) or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.

  本发明涉及用于治疗动物患病的组合物和方法，该疾病对通过向需要的哺乳动物投予本文所定义的化合物的有效量（包括表1-14中列出的那些化合物或被I-XII公式所包含的化合物）或其组合物来抑制功能性囊性纤维化跨膜传导调节蛋白（CFTR）多肽作出反应，从而治疗该疾病。本发明特别涉及一种治疗腹泻和多囊性肾病的方法。
• Multitarget-directed resveratrol derivatives: anti-cholinesterases, anti-β-amyloid aggregation and monoamine oxidase inhibition properties against Alzheimer's disease
  作者：Long-Fei Pan、Xiao-Bing Wang、Sai-Sai Xie、Su-Yi Li、Ling-Yi Kong

  DOI：10.1039/c3md00376k

  日期：——

  Resveratrol derivatives were designed and synthesized as multitarget-directed agents for treating AD, and 6r was a balanced inhibitor toward all the tested targets.

  白藜芦醇衍生物被设计并合成为治疗阿尔茨海默病的多靶向药物，其中6r是对所有测试靶点均具有平衡抑制作用的。
• Probing Fluorinated Motifs onto Dual AChE-MAO B Inhibitors: Rational Design, Synthesis, Biological Evaluation, and Early-ADME Studies
  作者：Mariagrazia Rullo、Marco Cipolloni、Marco Catto、Carolina Colliva、Daniela Valeria Miniero、Tiziana Latronico、Modesto de Candia、Tiziana Benicchi、Anna Linusson、Nicola Giacchè、Cosimo Damiano Altomare、Leonardo Pisani

  DOI：10.1021/acs.jmedchem.1c01784

  日期：2022.3.10

  Bioisosteric H/F or CH2OH/CF2H replacement was introduced in coumarin derivatives previously characterized as dual AChE-MAO B inhibitors to probe the effects on both inhibitory potency and drug-likeness. Along with in vitro screening, we investigated early-ADME parameters related to solubility and lipophilicity (Sol7.4, CHI7.4, log D7.4), oral bioavailability and central nervous system (CNS) penetration

  生物等排 H/F 或 CH 2 OH/CF 2 H 替代物被引入香豆素衍生物中，该衍生物以前被表征为双重 AChE-MAO B 抑制剂，以探测对抑制效力和药物相似性的影响。除了体外筛选，我们还研究了与溶解度和亲脂性（Sol 7.4、CHI 7.4、log  D 7.4）、口服生物利用度和中枢神经系统（CNS）渗透（PAMPA-HDM 和 PAMPA-血脑屏障）相关的早期 ADME 参数(BBB) 测定、Caco-2 双向转运研究）和代谢责任（微粒体中的半衰期和清除、CYP3A4 的抑制）。分别在 SH-SY5Y 和 HepG2 系中测定了特异性和非特异性组织毒性。化合物带有 -CF 2 H 基序的15作为水溶性、口服生物可利用的 CNS 渗透性强效抑制剂出现，可抑制人 AChE (IC 50 = 550 nM) 和 MAO B (IC 50 = 8.2 nM，B/A 选择性 > 1200)
• Compounds, Compositions and Methods Comprising Pyridazine Derivatives
  申请人：Russell Michael Geoffrey Neil

  公开号：US20090270398A1

  公开（公告）日：2009-10-29

  The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Table 1 or encompassed by formula I) or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.

  本发明涉及用于治疗动物患病的组合物和方法，该疾病对通过向需要的哺乳动物投予本文中定义的有效量的化合物（包括表1中列出的那些化合物或由公式I包含的化合物）或其组合物来抑制功能性囊性纤维化跨膜传导调节蛋白（CFTR）多肽产生响应，从而治疗该疾病。本发明特别涉及治疗腹泻和多囊肾病的方法。
• Novel Disulfiram Derivatives as ALDH1a1-Selective Inhibitors
  作者：Ziad Omran

  DOI：10.3390/molecules27020480

  日期：——

  Aldehyde dehydrogenase-1a1 (ALDH1a1), the enzyme responsible for the oxidation of retinal into retinoic acid, represents a key therapeutic target for the treatment of debilitating disorders such as cancer, obesity, and inflammation. Drugs that can inhibit ALDH1a1 include disulfiram, an FDA-approved drug to treat chronic alcoholism. Disulfiram, by carbamylation of the catalytic cysteines, irreversibly inhibits ALDH1a1 and ALDH2. The latter is the isozyme responsible for important physiological processes such as the second stage of alcohol metabolism. Given the fact that ALDH1a1 has a larger substrate tunnel than that in ALDH2, replacing disulfiram ethyl groups with larger motifs will yield selective ALDH1a1 inhibitors. We report herein the synthesis of new inhibitors of ALDH1a1 where (hetero)aromatic rings were introduced into the structure of disulfiram. Most of the developed compounds retained the anti-ALDH1a1 activity of disulfiram; however, they were completely devoid of inhibitory activity against ALDH2.

  醛脱氢酶-1a1（ALDH1a1）是将视黄醛氧化成视黄酸的酶，是治疗癌症、肥胖和炎症等疾病的关键治疗靶点。可以抑制ALDH1a1的药物包括二硫化物，这是一种FDA批准用于治疗慢性酗酒的药物。二硫化物通过对催化半胱氨酸的氨基甲酰化，不可逆地抑制ALDH1a1和ALDH2。后者是负责重要生理过程如酒精代谢的第二阶段的同工酶。鉴于ALDH1a1具有比ALDH2更大的底物通道，将二硫化物乙基基团替换为更大的基团将产生选择性ALDH1a1抑制剂。我们在此报告了引入（杂）芳香环到二硫化物结构中的ALDH1a1新抑制剂的合成。大多数开发的化合物保留了二硫化物的抗ALDH1a1活性；然而，它们完全没有对ALDH2的抑制活性。